NewsNCLT Directs Kopran Limited to Hold Stakeholder Meetings for Proposed Merger with Kopran LaboratoriesNCLT Directs Kopran Limited to Hold Stakeholder Meetings for Proposed Merger with Kopran Laboratories
Kopran Limited received NCLT Mumbai Bench directions on April 09, 2026, to conduct stakeholder meetings for its proposed merger with Kopran Laboratories Limited. The tribunal mandated separate meetings for equity shareholders, secured creditors, and unsecured creditors as part of the Scheme of Amalgamation under the Companies Act 2013. This development advances the merger by absorption process initially announced in March 2025, with the complete NCLT order now available on the company's website for stakeholder review.
*this image is generated using AI for illustrative purposes only.
Kopran Limited has received a significant regulatory milestone in its proposed merger process, with the National Company Law Tribunal (NCLT) Mumbai Bench directing the company to conduct mandatory stakeholder meetings. The development marks a crucial step forward in the pharmaceutical company's consolidation strategy.
NCLT Order Details
The Hon'ble NCLT Mumbai Bench issued its order on April 09, 2026, providing specific directions for the merger process. The tribunal has mandated Kopran Limited to organize separate meetings for different stakeholder categories as part of the amalgamation scheme.
| Meeting Type: | Stakeholder Category |
|---|---|
| Equity Shareholders Meeting: | All equity shareholders |
| Secured Creditors Meeting: | Secured creditors |
| Unsecured Creditors Meeting: | Unsecured creditors |
Merger Scheme Overview
The proposed transaction involves the Scheme of Amalgamation through merger by absorption of Kopran Laboratories Limited (Transferor Company) with Kopran Limited (Transferee Company). The scheme was initially announced in the company's letter dated March 20, 2025, and operates under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013.
| Parameter: | Details |
|---|---|
| Merger Type: | Merger by Absorption |
| Transferor Company: | Kopran Laboratories Limited |
| Transferee Company: | Kopran Limited |
| Legal Framework: | Companies Act 2013, Sections 230-232 |
| Status: | Subject to regulatory approvals |
Regulatory Compliance
The disclosure has been made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations. Company Secretary and Compliance Officer Sunil Sodhani signed the regulatory filing, ensuring compliance with stock exchange notification requirements.
Document Accessibility
The complete NCLT order is now publicly available on the company's official website at www.kopran.com . Stakeholders can access the detailed order through the dedicated link provided in the company's regulatory filing, ensuring transparency in the merger process.
The NCLT's direction represents a procedural advancement in the merger timeline, bringing the pharmaceutical company closer to completing its consolidation objectives. The mandated stakeholder meetings will provide the necessary forum for shareholders and creditors to review and approve the proposed amalgamation scheme.
Historical Stock Returns for Kopran
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.89% | +30.01% | +23.67% | -10.09% | -17.93% | +40.15% |
What potential synergies and cost savings could Kopran Limited achieve post-merger, and how might this impact its competitive position in the pharmaceutical market?
How will the merger affect Kopran's product portfolio diversification and its ability to compete with larger pharmaceutical companies?
What are the expected timelines for completing the stakeholder meetings and receiving final NCLT approval for the amalgamation?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
